Rivastigmine Tartrate
Product Images NDC 54868-6145

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Rivastigmine Tartrate (NDC 54868-6145). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Physicians Total Care, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label-6 mg (6mg Package Label)

Label for Rivastigmine Tartrate 6 mg distributed by Physicians Total Care, Inc. in Tulsa, Oklahoma, with product NDC 54868-6145-0. The label includes lot number 0000, an expiration date of 01/60, and states manufacturing by Sun Pharmaceuticals Ltd in Mumbai, India, along with a barcode.*

FDA Label Image

Rivastigmine-figure01 (Rivastigmine Fig1)

A line graph depicting the time-course of change from baseline in ADAS-cog scores for patients completing 26 weeks of treatment. The x-axis represents weeks during treatment (0, 12, 18, 26), and the y-axis shows the mean change from baseline in ADAS-cog score, ranging from -2 to 2. Three groups are shown: 6 to 12 mg, 1 to 4 mg, and placebo, with corresponding data points illustrating clinical improvement or decline over time.*

FDA Label Image

Rivastigmine-figure02 (Rivastigmine Fig2)

A cumulative percentage graph showing patients completing 26 weeks of double-blind treatment by change from baseline ADAS-cog scores. Three treatment groups are compared: placebo, 1 to 4 mg, and 6 to 12 mg of Rivastigmine Tartrate. The graph includes a table summarizing the percentage of patients with specific score changes in each group.*

FDA Label Image

Rivastigmine-figure03 (Rivastigmine Fig3)

A bar graph labeled 'Figure 3: Frequency Distribution of CIBIC-Plus Scores at Week 26' showing the percentage of patients on the y-axis and CIBIC-Plus plus rating categories on the x-axis, ranging from 'Markedly Improved' to 'Markedly Worse.' Three groups are compared: Placebo, 1 to 4 mg, and 6 to 12 mg, with separate bars for each group in each rating category.*

FDA Label Image

Rivastigmine-figure04 (Rivastigmine Fig4)

A line graph showing the time-course of change from baseline in ADAS-cog scores over 26 weeks of treatment for patients, comparing three groups: 6 to 12 mg, 1 to 4 mg, and placebo. The vertical axis represents mean change in ADAS-cog rating, with clinical improvement above zero and clinical decline below zero. Three lines with error bars illustrate the trends for each dosage group during the treatment period.*

FDA Label Image

Rivastigmine-figure05 (Rivastigmine Fig5)

A cumulative percentage line graph showing patients completing 26 weeks of double-blind treatment with Rivastigmine Tartrate, categorized by dose groups 6 to 12 mg, 1 to 4 mg, and placebo. The x-axis represents change from baseline in ADAS-cog scores, and the y-axis shows cumulative percentage of patients. A table within the graph displays mean changes in ADAS-cog scores for each treatment group (placebo, 1 to 4 mg/day, and 6 to 12 mg/day).*

FDA Label Image

Rivastigmine-figure06 (Rivastigmine Fig6)

A bar chart titled 'Frequency Distribution of CIBIC-Plus Scores at Week 26' showing percentage of patients on the y-axis and CIBIC-Plus Rating categories on the x-axis. Three groups are compared: Placebo, 1 to 4 mg, and 6 to 12 mg, with varying frequencies across categories from 'Markedly Improved' to 'Markedly Worse'.*

FDA Label Image

Rivastigmine-figure07 (Rivastigmine Fig7)

A line graph titled 'Time course of the Change from Baseline in ADAS-cog Score for Patients Completing 24 Weeks of Treatment' comparing Rivastigmine Tartrate Capsules and Placebo. The x-axis shows weeks during treatment (0, 8, 16, 24), and the y-axis shows mean change from baseline in ADAS-cog rating. The Rivastigmine Tartrate group shows increasing improvement, while the placebo group fluctuates near baseline. The graph indicates clinical improvement is a lower ADAS-cog score and clinical decline is a higher score.*

FDA Label Image

Rivastigmine-figure08 (Rivastigmine Fig8)

A bar chart showing the distribution of ADCS-CGIC scores for patients completing 24 weeks of treatment, comparing Rivastigmine Tartrate Capsules and placebo. The x-axis lists categories from markedly improved to markedly worse, and the y-axis shows the percentage of patients in each category.*

FDA Label Image

Rivastigmine-chemical-structure (Rivastigmine Str)

Chemical structure of the active ingredient Rivastigmine Tartrate, illustrating the molecular composition including a phenyl ring, carbonyl groups, and various alkyl substituents, alongside its tartrate component (C4H6O6).*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.